Redwood City, CA – According to filings with the U.S. Securities and Exchange Commission, Bolt Biotherapeutics is raising $93,499,984.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, William Quinn played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Bolt Biotherapeutics

Bolt Biotherapeutics was founded in 2015 by Dr. Edgar G. Engleman of Stanford University to expand upon his pioneering work in cancer immunotherapeutics and myeloid biology. Bolt is based in the San Francisco Bay area. Bolt’s highly qualified management team includes experienced leaders in immuno-oncology drug discovery, development and commercialization. Our goal is to leverage our myeloid biology expertise to discover, develop and commercialize transformative treatments to address key unmet medical needs for patients with cancer.

To learn more about Bolt Biotherapeutics, visit http://boltbio.com/

Contact:
William Quinn, Chief Financial Officer
650-665-9295
https://www.linkedin.com/in/williequinn/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved